8-K: Estrella Biopharma Enters $33 Million Clinical Trial Agreement with Eureka Therapeutics for EB103

Estrella Biopharma has engaged Eureka Therapeutics for clinical trial services for its EB103 cancer therapy, with a total contract value of $33 million.

Summary

• Estrella Biopharma has entered into a Statement of Work (SOW) with Eureka Therapeutics for clinical trial services related to its EB103 anti-CD19 ARTEMIS therapy.
• The SOW outlines a $33 million agreement for a Phase I/II clinical trial, assuming 20 patients are dosed and one clinical site is activated.
• The agreement includes study start-up, patient dosing, study close-out, and reporting phases.
• Eureka will provide services such as regulatory document development, site activation, patient enrollment, data collection, and pharmacovigilance.
• The payment structure includes milestone-based payments, with an initial $3.5 million due upon execution of the SOW, a $1.5 million deposit before patient dosing, $1.375 million per patient dosed, and $2 million upon study close-out.
• An additional $500,000 will be paid if a second clinical site is activated.
• The estimated timeline includes dosing 6 patients by the end of 2024 and an additional 14 patients by the end of 2025.
• Eureka will also invoice Estrella Biopharma quarterly for pass-through costs and expenses.
• Estrella Biopharma is responsible for all taxes, fees, and duties related to the services, excluding taxes on Eureka's income.
• Eureka, as the controlling shareholder of Estrella Immunopharma, will cooperate to ensure Estrella Biopharma can secure financing to meet its payment obligations under the SOW.

Sentiment

Score: 7

Explanation: The document outlines a significant agreement for a clinical trial, which is positive for the company's development. However, the financial obligations and potential risks associated with the trial temper the overall sentiment.

Positives

• The agreement provides a clear framework for the clinical trial of EB103.
• The milestone-based payment structure aligns payments with the progress of the trial.
• Eureka's cooperation in securing financing for Estrella Biopharma is a positive sign.
• The SOW includes detailed services for all phases of the clinical trial, from start-up to close-out.

Negatives

• The agreement includes a non-refundable net fee structure.
• Estrella Biopharma is responsible for all pass-through costs and expenses, which could increase the total cost of the trial.
• The timeline is estimated and subject to variation, which could lead to delays and additional costs.
• Estrella Biopharma is responsible for all taxes, fees, and duties related to the services, excluding taxes on Eureka's income.

Risks

• Failure to meet enrollment targets at the initial sites may require additional site activation and costs.
• Significant increases in vendor and site costs beyond the annual inflation rate could lead to renegotiation of financial terms.
• Delays in the clinical trial could impact the timeline and increase costs.
• Estrella Biopharma's ability to secure sufficient financing to meet its payment obligations is crucial for the success of the trial.
• The agreement allows for termination or suspension of services by either party under certain conditions, which could disrupt the trial.

Future Outlook

The document outlines the financial and operational framework for the clinical trial of EB103, with estimated timelines for patient dosing and study completion. The success of the trial and the ability of Estrella Biopharma to secure financing will be critical for future progress.

Management Comments

• Eureka, as the controlling shareholder of ESLA, agrees to cooperate with Client and/or ESLA, to take all reasonable actions necessary in order for Client and/or ESLA to consummate financing transactions sufficient to pay the amounts payable by Client pursuant to this SOW while maintaining ESLAs compliance with Nasdaq listing standards and applicable state and federal law.

Industry Context

This agreement is part of the broader trend of biotech companies outsourcing clinical trial services to specialized providers. The focus on T-cell therapy and the use of ARTEMIS technology aligns with current advancements in cancer treatment.

Comparison to Industry Standards

• The contract value of $33 million for a Phase I/II clinical trial is within the typical range for similar studies, but can vary based on the complexity of the trial, the number of patients, and the specific services included.
• The per-patient dosing fee of $1.375 million is relatively high, reflecting the complexity of cell therapy trials.
• The milestone-based payment structure is a common practice in clinical trial agreements, aligning payments with the progress of the study.
• Companies like ICON plc and IQVIA are major players in the clinical research organization (CRO) space, and this agreement is similar to contracts they would undertake, although Eureka is not a CRO in the traditional sense.
• The use of a controlling shareholder to provide clinical trial services is not typical and may raise questions about conflicts of interest.

Related Party Transactions

• The agreement is between Estrella Biopharma and Eureka Therapeutics, with Eureka being the controlling shareholder of Estrella Immunopharma, indicating a related party transaction.

Stakeholder Impact

• Shareholders of Estrella Immunopharma will be impacted by the financial obligations and potential success of the clinical trial.
• Employees of Estrella Biopharma and Eureka will be involved in the execution of the trial.
• Patients with relapsed or refractory B-cell non-Hodgkin lymphoma may benefit from the EB103 therapy if the trial is successful.
• Suppliers and vendors will be engaged to support the clinical trial.

Next Steps

• Estrella Biopharma will initiate the study start-up phase, including regulatory document development and site selection.
• Eureka will begin providing services as outlined in the SOW.
• Estrella Biopharma will need to secure financing to meet its payment obligations.
• The first patient is expected to be dosed in 2024.

Key Dates

Keywords

clinical trial, EB103, Eureka Therapeutics, Estrella Biopharma, ARTEMIS T-cell therapy, milestone payments, patient dosing, study start-up, regulatory approvals, pharmacovigilance